Cargando…

Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients

Purpose. Angiosarcoma is a rare tumor with endothelial cell differentiation that may arise in any anatomic location.The purpose of this report was to identify prognostic factors on outcome in a group of prospectively followed patients with confirmed angiosarcoma. Subjects. Adult patients (>16 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Espat, N. J., Lewis, J. J., Woodruff, J. M., Antonescu, C., Xia, J., Leung, D., M. F., Brennan
Formato: Texto
Lenguaje:English
Publicado: Sarcoma 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395443/
https://www.ncbi.nlm.nih.gov/pubmed/18521298
http://dx.doi.org/10.1155/2000/575781
_version_ 1782155507663896576
author Espat, N. J.
Lewis, J. J.
Woodruff, J. M.
Antonescu, C.
Xia, J.
Leung, D.
M. F., Brennan
author_facet Espat, N. J.
Lewis, J. J.
Woodruff, J. M.
Antonescu, C.
Xia, J.
Leung, D.
M. F., Brennan
author_sort Espat, N. J.
collection PubMed
description Purpose. Angiosarcoma is a rare tumor with endothelial cell differentiation that may arise in any anatomic location.The purpose of this report was to identify prognostic factors on outcome in a group of prospectively followed patients with confirmed angiosarcoma. Subjects. Adult patients (>16 years old) with angiosarcoma treated between July 1982 and February 1998 were identified from a prospective database. Methods. Pathologic confirmation of all cases was performed prior to inclusion in this analysis. Various prognostic factors were evaluated for disease-specific survival. Survival was determined by the Kaplan– Meier method. Statistical significance was evaluated by log-rank test for univariate analysis and Cox stepwise regression for multivariate analysis (p < 0.05). Results. Fifty patients were identified; at the initial evaluation, this group included 32 patients with a primary tumor, three with local recurrence and 15 with metastatic disease. Tumor sites included 16 head and neck and skin of head, eight extremity, seven trunk, six breast, five pelvis, four viscera and four thoracic. Median follow-up among survivors was 71 months (range, 38–191 months).Two- and 5-year disease-specific survival was 50 and 30%, respectively, with a median of 24 months. The factor predictive of tumor-related mortality was presentation status (p=0.001; relative risk, 5). Two-year disease-specific survival for patients presenting with recurrent or metastatic disease was 13%, compared with 70% for those with primary disease.
format Text
id pubmed-2395443
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Sarcoma
record_format MEDLINE/PubMed
spelling pubmed-23954432008-06-02 Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients Espat, N. J. Lewis, J. J. Woodruff, J. M. Antonescu, C. Xia, J. Leung, D. M. F., Brennan Sarcoma Clinical Study Purpose. Angiosarcoma is a rare tumor with endothelial cell differentiation that may arise in any anatomic location.The purpose of this report was to identify prognostic factors on outcome in a group of prospectively followed patients with confirmed angiosarcoma. Subjects. Adult patients (>16 years old) with angiosarcoma treated between July 1982 and February 1998 were identified from a prospective database. Methods. Pathologic confirmation of all cases was performed prior to inclusion in this analysis. Various prognostic factors were evaluated for disease-specific survival. Survival was determined by the Kaplan– Meier method. Statistical significance was evaluated by log-rank test for univariate analysis and Cox stepwise regression for multivariate analysis (p < 0.05). Results. Fifty patients were identified; at the initial evaluation, this group included 32 patients with a primary tumor, three with local recurrence and 15 with metastatic disease. Tumor sites included 16 head and neck and skin of head, eight extremity, seven trunk, six breast, five pelvis, four viscera and four thoracic. Median follow-up among survivors was 71 months (range, 38–191 months).Two- and 5-year disease-specific survival was 50 and 30%, respectively, with a median of 24 months. The factor predictive of tumor-related mortality was presentation status (p=0.001; relative risk, 5). Two-year disease-specific survival for patients presenting with recurrent or metastatic disease was 13%, compared with 70% for those with primary disease. Sarcoma 2000-12-22 /pmc/articles/PMC2395443/ /pubmed/18521298 http://dx.doi.org/10.1155/2000/575781 Text en Copyright © 2000 Hindawi Publishing Corporation https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Espat, N. J.
Lewis, J. J.
Woodruff, J. M.
Antonescu, C.
Xia, J.
Leung, D.
M. F., Brennan
Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title_full Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title_fullStr Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title_full_unstemmed Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title_short Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
title_sort confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395443/
https://www.ncbi.nlm.nih.gov/pubmed/18521298
http://dx.doi.org/10.1155/2000/575781
work_keys_str_mv AT espatnj confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT lewisjj confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT woodruffjm confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT antonescuc confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT xiaj confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT leungd confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients
AT mfbrennan confirmedangiosarcomaprognosticfactorsandoutcomein50prospectivelyfollowedpatients